Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Takeda Pharmaceutical Company Limited    4502   JP3463000004

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 million

12/26/2019 | 11:43pm EST
Astellas Pharma's logo is pictured at its headquarters in Tokyo

Astellas Pharma Inc has bought U.S.-based Xyphos Biosciences Inc to expand its immuno-oncology business, a deal worth up to $665 million including potential development milestones and its second acquisition announced this month.

Japan's second biggest drugmaker by sales paid $120 million upfront for Xyphos and the rest will be milestone payments, the companies said in a statement.

Astellas also said this month it had agreed to purchase Audentes Therapeutics Inc for about $3 billion to expand its push into genetic medicines. The deal is due to close in January.

Immuno-oncology, which seeks to use the body's own defense systems to fight cancer, is a primary focus for Astellas and under the deal, the Japanese firm will gain Xyphos' cell therapy technology platform and its research team.

"Combining this technology with our capabilities in cell therapy that we have been working on so far, we can create next-generation high-function cells and maximize the value of our technology," Astellas President Kenji Yasukawa said in the statement.

Xyphos' proprietary molecules can be delivered to natural immune cells or to engineered Chimeric Antigen Receptor (CAR) cells to generate immunotherapies for oncology.

Xyphos' first CAR cell product candidate is in preclinical development and is scheduled to be tested in a first-in-human clinical study in 2021, the statement said.

Both Xyphos and Audentes are based in San Francisco, a hub for biotech companies that are fetching huge premiums for global pharma companies eager to bolster their drug pipelines.

Japanese companies have agreed to more than 30 overseas acquisitions worth about $6 billion in the healthcare sector this year, according to Refinitiv data. That's still dwarfed by the $59 billion takeover of Britain's Shire Plc by Japanese market leader Takeda Pharmaceutical Co Ltd announced in 2018.

Astellas' purchase of Audentes was its second biggest on record after its 2010 purchase of OSI Pharmaceuticals Inc for $3.8 billion.

In the wake of the Audentes deal, Moody's put its A1 ratings on Astellas under review for a downgrade, saying the company's willingness to use debt to fund the purchase, worth 8 times the target's book equity, signaled an "an urgency for Astellas to feed its long-term product pipeline."

Shares in Astellas gained 0.7%, outperforming a largely flat broader market <.N225> ahead of the New Year holiday.

By Rocky Swift


© Reuters 2019
Stocks mentioned in the article
ChangeLast1st jan.
ASTELLAS PHARMA INC. 2.08% 1720 End-of-day quote.7.90%
BYD COMPANY LIMITED 9.35% 278.4 End-of-day quote.37.01%
HUB CO., LTD. 2.81% 622 End-of-day quote.14.76%
NEXT PLC 1.98% 8036 Delayed Quote.13.41%
ONE STOP SYSTEMS, INC. -4.58% 3.75 Delayed Quote.-6.25%
TAKEDA PHARMACEUTICAL COMPANY LIMITED 3.54% 3714 End-of-day quote.-1.09%
TEAM, INC. -5.94% 10.77 Delayed Quote.-1.19%
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
01/27TAKEDA PHARMACEUTICAL : Achieved Carbon Neutrality in 2020
PU
01/26TAKEDA PHARMACEUTICAL : Achieves Industry-Leading Positions in 2021 Access to Me..
BU
01/26Japan shares end lower on vaccine delay, caution ahead of earnings season
RE
01/25Japan stocks slip on vaccine worries, profit-taking ahead of earnings
RE
01/25TAKEDA PHARMACEUTICAL : Manufacturing and Marketing Approval Received in Japan f..
AQ
01/25Japanese shares gain tracking U.S. futures; tech and pharma stocks boost
RE
01/24Japanese shares track U.S. futures higher, tech leads gains
RE
01/24TAKEDA PHARMACEUTICAL : Named Global Top Employer for Fourth Consecutive Year
PU
01/22TAKEDA PHARMACEUTICAL : Manufacturing and Marketing Approval Received in Japan f..
PU
01/21TAKEDA PHARMACEUTICAL : Starts Clinical Trial of Moderna's COVID-19 Vaccine Cand..
MT
More news
Financials
Sales 2021 3 233 B 30 981 M 30 981 M
Net income 2021 202 B 1 937 M 1 937 M
Net Debt 2021 3 840 B 36 807 M 36 807 M
P/E ratio 2021 35,5x
Yield 2021 4,78%
Capitalization 5 889 B 56 589 M 56 442 M
EV / Sales 2021 3,01x
EV / Sales 2022 2,82x
Nbr of Employees 47 495
Free-Float 99,1%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Average target price 5 150,00 JPY
Last Close Price 3 767,00 JPY
Spread / Highest target 72,6%
Spread / Average Target 36,7%
Spread / Lowest Target 8,84%
EPS Revisions
Managers and Directors
NameTitle
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Yasuhiko Yamanaka Director
Sector and Competitors
1st jan.Capitalization (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-1.09%56 589
JOHNSON & JOHNSON6.67%448 796
ROCHE HOLDING AG4.51%312 213
NOVARTIS AG0.81%214 457
PFIZER INC.-1.55%207 384
MERCK & CO., INC.-1.89%203 035